Boehringer Ingelheim has announced that its LUME-Colon 1 study has met one of the co-primary endpoints of progression-free survival (PFS) in pre-treated patients with metastatic colorectal cancer (mCRC).

The study investigated nintedanib plus best supportive care (BSC) versus BSC alone in mCRC patients who did not respond to other treatments.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Although nintedanib indicated clear anti-tumour activity and significantly reduced the risk of disease progression by 42% versus BSC, this did not show an overall survival (OS) benefit, the second co-primary endpoint.

"Nintedanib is an active compound and had a significant effect in stabilising disease for patient."

The data indicated that the types of adverse events were consistent with those observed in previous nintedanib oncology trials, with no new or unexpected safety signals.

Belgium's University of Leuven professor of internal medicine and lead investigator professor Eric Van Cutsem said: "The data confirmed nintedanib is an active compound and had a significant effect in stabilising disease for patients with advanced colorectal cancer.

See Also:

“Unfortunately, this benefit did not lead to an increase in overall survival and we are currently analysing the data to better understand this outcome."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Boehringer Ingelheim vice president and global head of medicine for oncology Mehdi Shahidi said: "The ultimate goal of our oncology programmes is to develop treatments that will change clinical practice to benefit the lives of patients and their families.

“While the outcome of the LUME-Colon 1 trial is not what we had hoped for, we continue to learn and evolve our research strategy with every study result from our development programme."

Nintedanib is being tested with other cancers, such as malignant pleural mesothelioma (MPM).

Data from the Phase II LUME-Meso [NCT01907100] trial investigating nintedanib for patients with MPM will be presented  in December. 

Patients are currently being recruited for Phase III of the study.